[The combined use of artemether, sulfadoxine, pyrimethamine and primaquine in the treatment of chloroquine-resistant falciparum malaria].
D000328:Adult; D000818:Animals; D000962:Antimalarials / Q000627:therapeutic use*; D000077549:Artemether; D037621:Artemisinins; D002648:Child; D002738:Chloroquine / Q000494:pharmacology; D004352:Drug Resistance, Microbial; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D008288:Malaria / Q000188:drug therapy*; D008297:Male; D010963:Plasmodium falciparum / Q000187:drug effects; D011319:Primaquine / Q000627:therapeutic use; D011714:Pyrans / Q000627:therapeutic use; D011739:Pyrimethamine / Q000627:therapeutic use; D012717:Sesquiterpenes; D013413:Sulfadoxine / Q000627:therapeutic use
D000962:Antimalarials; D037621:Artemisinins; D011714:Pyrans; D012717:Sesquiterpenes; D013413:Sulfadoxine; D002738:Chloroquine; D000077549:Artemether; D011319:Primaquine; D011739:Pyrimethamine